• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有结合活性的无二硫键单域 V(L) 内体可识别亨廷顿蛋白的新型表位。

A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition.

机构信息

Munich Center for Integrated Protein Science and Lehrstuhl für Biologische Chemie, Technische Universität München, 85350 Freising-Weihenstephan, Germany.

出版信息

J Mol Biol. 2011 Dec 2;414(3):337-55. doi: 10.1016/j.jmb.2011.09.034. Epub 2011 Sep 24.

DOI:10.1016/j.jmb.2011.09.034
PMID:21968397
Abstract

We present the crystal structure and biophysical characterization of a human V(L) [variable domain immunoglobulin (Ig) light chain] single-domain intrabody that binds to the huntingtin (Htt) protein and has been engineered for antigen recognition in the absence of its intradomain disulfide bond, otherwise conserved in the Ig fold. Analytical ultracentrifugation demonstrated that the αHtt-V(L) 12.3 domain is a stable monomer under physiological conditions even at concentrations >20 μM. Using peptide SPOT arrays, we identified the minimal binding epitope to be EKLMKAFESLKSFQ, comprising the N-terminal residues 5-18 of Htt and including the first residue of the poly-Gln stretch. X-ray structural analysis of αHtt-V(L) both as apo protein and in the presence of the epitope peptide revealed several interesting insights: first, the role of mutations acquired during the combinatorial selection process of the αHtt-V(L) 12.3 domain-initially starting from a single-chain Fv fragment-that are responsible for its stability as an individually soluble Ig domain, also lacking the disulfide bridge, and second, a previously unknown mode of antigen recognition, revealing a novel paratope. The Htt epitope peptide adopts a purely α-helical structure in the complex with αHtt-V(L) and is bound at the base of the complementarity-determining regions (CDRs) at the concave β-sheet that normally gives rise to the interface between the V(L) domain and its paired V(H) (variable domain Ig heavy chain) domain, while only few interactions with CDR-L1 and CDR-L3 are formed. Notably, this noncanonical mode of antigen binding may occur more widely in the area of in vitro selected antibody fragments, including other Ig-like scaffolds, possibly even if a V(H) domain is present.

摘要

我们展示了一个与人 V(L)[可变域免疫球蛋白(Ig)轻链]单域内体的晶体结构和生物物理特性,该内体与亨廷顿(Htt)蛋白结合,并经过工程改造,使其在没有其域内二硫键的情况下识别抗原,而该二硫键在 Ig 折叠中是保守的。分析超速离心表明,αHtt-V(L)12.3 结构域在生理条件下即使在浓度高于 20μM 时也是稳定的单体。使用肽 SPOT 阵列,我们确定最小结合表位为 EKLMKAFESLKSFQ,包含 Htt 的 N 端残基 5-18,包括聚谷氨酰胺延伸的第一个残基。αHtt-V(L)的 X 射线结构分析无论是在apo 蛋白还是在表位肽存在的情况下,都揭示了几个有趣的见解:首先,在αHtt-V(L)12.3 结构域的组合选择过程中获得的突变的作用-最初从单链 Fv 片段开始-负责其作为单独可溶 Ig 结构域的稳定性,也缺乏二硫键,其次,一种以前未知的抗原识别模式,揭示了一种新的抗原决定簇。Htt 表位肽在与αHtt-V(L)的复合物中采用纯α-螺旋结构,并且结合在互补决定区(CDRs)的底部,位于通常产生 V(L)结构域与其配对 V(H)[可变域 Ig 重链]结构域之间界面的凹面β-折叠处,而仅与 CDR-L1 和 CDR-L3 形成少量相互作用。值得注意的是,这种非典型的抗原结合模式可能更广泛地发生在体外选择的抗体片段区域,包括其他 Ig 样支架,即使存在 V(H)结构域也是如此。

相似文献

1
A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition.具有结合活性的无二硫键单域 V(L) 内体可识别亨廷顿蛋白的新型表位。
J Mol Biol. 2011 Dec 2;414(3):337-55. doi: 10.1016/j.jmb.2011.09.034. Epub 2011 Sep 24.
2
Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display.通过酵母表面展示技术开发针对亨廷顿蛋白氨基末端的人轻链可变区(V(L))细胞内抗体。
J Mol Biol. 2004 Sep 17;342(3):901-12. doi: 10.1016/j.jmb.2004.07.054.
3
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.一种无二硫键的单结构域细胞内抗体对亨廷顿蛋白聚集和细胞毒性的强效抑制作用
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17616-21. doi: 10.1073/pnas.0408134101. Epub 2004 Dec 14.
4
Crystal structure of an Fab fragment in complex with a meningococcal serosubtype antigen and a protein G domain.与脑膜炎球菌血清亚型抗原及蛋白G结构域结合的Fab片段的晶体结构
J Mol Biol. 1999 Oct 15;293(1):81-91. doi: 10.1006/jmbi.1999.3144.
5
NMR analysis of the interaction between protein L and Ig light chains.蛋白质L与免疫球蛋白轻链相互作用的核磁共振分析
J Mol Biol. 1997 Jul 4;270(1):8-13. doi: 10.1006/jmbi.1997.1090.
6
Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.鉴定重链第三个互补决定区带有二硫键的高亲和力人源抗体。
J Mol Recognit. 2012 Mar;25(3):125-35. doi: 10.1002/jmr.1168.
7
X-ray crystallography reveals stringent conservation of protein fold after removal of the only disulfide bridge from a stabilized immunoglobulin variable domain.X射线晶体学研究表明,从稳定的免疫球蛋白可变结构域中去除唯一的二硫键后,蛋白质折叠结构仍能严格保持。
Fold Des. 1997;2(6):357-61. doi: 10.1016/S1359-0278(97)00049-7.
8
Biophysical properties of human antibody variable domains.人抗体可变区的生物物理特性。
J Mol Biol. 2003 Jan 17;325(3):531-53. doi: 10.1016/s0022-2836(02)01237-8.
9
Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70.人线粒体转位酶受体Tom70特异性IgNAR可变结构域的分离与鉴定
Eur J Biochem. 2003 Sep;270(17):3543-54. doi: 10.1046/j.1432-1033.2003.03737.x.
10
Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold.具有种系支架的可溶性、可重折叠人源V(H)单结构域HEL4的晶体结构
J Mol Biol. 2004 Apr 2;337(4):893-903. doi: 10.1016/j.jmb.2004.02.013.

引用本文的文献

1
Ubiquitin-derived artificial binding proteins targeting oncofetal fibronectin reveal scaffold plasticity by β-strand slippage.靶向癌胚纤维连接蛋白的泛素衍生人工结合蛋白通过 β-链滑动揭示支架可塑性。
Commun Biol. 2024 Jul 27;7(1):907. doi: 10.1038/s42003-024-06569-9.
2
Crystal Structure of Designed Coiled-Coil Protein Origami Triangle.设计的螺旋蛋白折纸三角形的晶体结构。
J Am Chem Soc. 2023 Aug 9;145(31):16995-17000. doi: 10.1021/jacs.3c05531. Epub 2023 Jul 24.
3
Application of antihelix antibodies in protein structure determination.
抗螺旋抗体在蛋白质结构测定中的应用。
Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17786-17791. doi: 10.1073/pnas.1910080116. Epub 2019 Aug 1.
4
Intracellular targeting with engineered proteins.利用工程蛋白进行细胞内靶向
F1000Res. 2016 Aug 10;5. doi: 10.12688/f1000research.8915.1. eCollection 2016.
5
Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.与亨廷顿蛋白17个N端残基结合的单链抗体可变区片段结构为致病性淀粉样蛋白的形成及抑制机制提供了见解。
J Mol Biol. 2015 Jun 19;427(12):2166-78. doi: 10.1016/j.jmb.2015.03.021. Epub 2015 Apr 8.
6
Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.复合物的差异性核定位可能是亨廷顿舞蹈病体内抗体药物疗效的基础。
Protein Eng Des Sel. 2014 Oct;27(10):359-63. doi: 10.1093/protein/gzu041.
7
Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.抗体轻链可变区及其用于人体免疫治疗的物理性质改良版本。
MAbs. 2014 Jan-Feb;6(1):219-35. doi: 10.4161/mabs.26844.
8
Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.基于工程化人抗体结构域发现新型候选治疗药物和诊断方法。
Curr Drug Discov Technol. 2014 Mar;11(1):28-40. doi: 10.2174/15701638113109990032.
9
Intrabodies as neuroprotective therapeutics.内抗体作为神经保护治疗剂。
Neurotherapeutics. 2013 Jul;10(3):447-58. doi: 10.1007/s13311-013-0193-6.
10
Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties.动力学竞争的亨廷顿聚集途径控制淀粉样蛋白的多态性和性质。
Biochemistry. 2012 Apr 3;51(13):2706-16. doi: 10.1021/bi3000929. Epub 2012 Mar 20.